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Pandomized Evaluation of the TriActiv
alloon-Protection Flush and Extraction System
or the Treatment of Saphenous Vein Graft Disease
oseph P. Carrozza, JR, MD, FACC,* Michael Mumma, MD, FACC,†
effrey A. Breall, MD, PHD, FACC,‡ Aland Fernandez, MD, FACC,§ Eugene Heyman, PHD,
hristopher Metzger, MD, FACC,¶ for the PRIDE Study Investigators
oston, Massachusetts; Sarasota and Clearwater, Florida; Indianapolis, Indiana; Montgomery Village, Maryland;
nd Kingsport, Tennessee
OBJECTIVES The Protection During Saphenous Vein Graft Intervention to Prevent Distal Embolization
(PRIDE) study compared outcomes with the TriActiv System (Kensey Nash Corp., Exton,
Pennsylvania), a balloon-protection flush and extraction device, with an embolic protection
group during treatment of saphenous venous grafts (SVGs).
BACKGROUND Treatment of SVGs with embolic protection reduces adverse cardiac events.
METHODS We conducted a prospective trial randomizing 631 patients with coronary ischemia and
lesions in SVGs to embolic protection with the TriActiv System or control group (Guardwire
System [Medtronic AVE, Santa Rosa, California] or Filterwire EX [Boston Scientific Corp.,
Maple Grove, Minnesota]).
RESULTS The incidence of major adverse cardiac events at 30 days was 11.2% for the TriActiv group
and 10.1% for the control group (relative risk  1.1%; 95% confidence interval 0.67 to 1.76;
p  0.65; p  0.02 for non-inferiority). Safety and efficacy end points were similar between
groups except that patients randomized to the TriActiv System had more hemorrhagic
complications (10.9% vs. 5.4%; p  0.01).
CONCLUSIONS The TriActiv System was not inferior to approved embolic protection devices for the
treatment of diseased SVGs. (J Am Coll Cardiol 2005;46:1677–83) © 2005 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.06.073American College of Cardiology Foundation
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Tercutaneous catheter intervention (PCI) for saphenous
ein graft (SVG) disease is associated with significant
yonecrosis, increasing the risk of late mortality (1). The
athophysiology of embolization is multifactorial, involving
iberation of thrombus and atheromatous debris and soluble
ediators of vasoconstriction (2,3). The Saphenous Vein
raft Angioplasty Free of Emboli, Randomized (SAFER)
rial demonstrated that PCI performed with embolic pro-
ection was associated with a lower incidence of no-reflow,
eri-procedural myocardial infarction and adverse events
4). The FilterWire EX Randomized Evaluation (FIRE)
rial reported that use of the Filterwire EX (Boston Scien-
ific Corp., Maple Grove, Minnesota) offered protection
gainst distal embolization similar to the balloon-occlusion
uardwire System (Medtronic AVE, Santa Rosa, Califor-
ia) (5).
The SAFER and FIRE studies established that embolic
rotection with either balloon-occlusion or a filter was the
rst approach to improve outcome during SVG PCI. These
evices were difficult to use, however, and did not prevent
From the *Section of Interventional Cardiology-Beth Israel Deaconess Medical
enter, Boston, Massachusetts; †Sarasota Memorial Hospital, Sarasota, Florida;
Krannert Institute of Cardiology, Indiana University of Medicine, Indianapolis,
ndiana; §Morton Plant Hospital, Clearwater Cardiovascular & Interventional
onsultants, Clearwater, Florida; Montgomery Village, Maryland; and the ¶Well-
ont Holston Valley Medical Center, Kingsport, Tennessee. Drs. Carrozza,
umma, and Metzger served as members of the Scientific Advisory Board for the
ensey Nash Corp., the sponsor of this study.i
Manuscript received February 28, 2005; revised manuscript received June 17, 2005,
ccepted June 21, 2005.dverse events in 8% to 10% of patients. These limitations
ed to the development of a number of newer balloon-
cclusion and filter devices. The multicenter, randomized
rotection During Saphenous Vein Graft Intervention to
revent Distal Embolization (PRIDE) study compared PCI
f SVGs with a novel embolic protection system, TriActiv
Kensey Nash Corp., Exton, Pennsylvania), to the Guard-
ire (Medtronic AVE) and Filterwire EX (Boston Scien-
ific Corp.) devices.
ETHODS
riActiv balloon protected flush extraction system. The
omponents of the TriActiv System have been described
reviously (6). The lesion is crossed with the 0.014-inch
hieldwire temporary occlusion balloon guidewire and the
alloon (expansion range 3 to 5 mm) inflated via CO2-filled
yringe. After intervention, the FlushCath catheter is at-
ached side-to-side to the Shieldwire and advanced to the
cclusion balloon. Saline is infused at 50 cc/min through the
lushCath catheter by a sterile unit (autostream flow control
n  70]). This replaced a free standing, drive console used
n the early part of the PRIDE study (n  273). The
ffluent is extracted through the guiding catheter (200
c/min through 8-F guiding catheters or 125 cc/min with
-F guiding catheters). The balloon is deflated, and flow
estored.
he PRIDE study. The PRIDE study was a “hybrid”nvestigation (Fig. 1). At the commencement of the study,
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Evaluation of TriActiv System in the PRIDE Study November 1, 2005:1677–83ne embolic protection device was approved in the U.S.
nvestigators randomized patients to protection with the
riActiv System versus PCI without embolic protection
“Cohort I”), to demonstrate superiority of the TriActiv
ystem compared with an “unprotected” group. To demon-
trate non-inferiority of the TriActiv System compared with
“protected” control group, investigators randomized pa-
ients to protection with TriActiv or another protection
ystem approved for use in SVGs (“Cohort II”). Once a site
nrolled a patient in Cohort II, future enrollment was
imited to Cohort II. Each site enrolled a minimum of two
o six “roll-in” patients. The PRIDE study was approved by
he institutional review board at each site; all patients
rovided written informed consent to participate.
ntry criteria. Criteria for inclusion were age 21 years,
ngina or objective evidence of ischemia, lesion in a SVG
3.0 mm and 5.0 mm), Thrombolysis In Myocardial
nfarction (TIMI) flow grade 0, and ability to provide
nformed consent. Patients were excluded if any of the
ollowing were present: pregnancy, lesion in a native artery
r internal mammary graft, distal shoulder of the lesion
ithin 2.0 cm of the distal anastomosis, left ventricular
jection fraction 25%, sequential grafts unless the lesion
as 2 cm proximal to the branch point, myocardial
nfarction (creatine kinase [CK] and CK-MB more than
wice the upper limit of normal within 24 h), allergy to
spirin or both clopidogrel and ticlopidine, treatment of 2
Abbreviations and Acronyms
FIRE  FilterWire EX Randomized Evaluation
MACE  major adverse cardiac events
MI  myocardial infarction
PCI  percutaneous coronary intervention
PRIDE  Protection During Saphenous Vein Graft
Intervention to Prevent Distal Embolization
trial
SAFER  Saphenous Vein Graft Angioplasty Free of
Emboli, Randomized study
SVG  saphenous vein/venous graft
TIMI  Thrombolysis In Myocardial Infarction
TLR  target lesion revascularization
TVR  target vessel revascularizationrFigure 1. Enrollment in the PRIDE study.VGs, and co-morbidities limiting life-expectancy to 6
onths.
Randomization was stratified by intention to administer a
lycoprotein IIb/IIIa receptor antagonist before interven-
ion. Patients received aspirin before the procedure and
ither heparin or bivalirudin during the procedure. After the
rocedure, aspirin and either clopidogrel or ticlopidine were
dministered for a minimum of one month. Cardiac en-
ymes were assessed every 8 h for 24 h. Patients were
ssessed clinically at 30 days.
respecified study end points. Device success was defined
s delivery of the device to the target location with successful
peration and removal of the device. Lesion success was
efined as the attainment of 50% residual stenosis at the
nd of the procedure. Procedure success was defined as
evice success without a major adverse cardiac event
MACE). The primary end point was MACE (either
ardiac death, myocardial infarction [any post-procedure
K-MB level 3  the upper limit of normal], or target
esion revascularization) at 30 days. Pre-specified efficacy
nd safety end points were device success and final TIMI
ow grade, myocardial infarction, in-hospital MACE,
troke at 30 days, and major vascular complications (perfo-
ation, hematoma at access site 5 cm, false aneurysm,
rteriovenous fistula, retroperitoneal hemorrhage, peripheral
schemia/nerve injury, vascular repair, ultrasound compres-
ion, and transfusion).
tudy organization (Appendix). Electrocardiograms and
ngiograms were analyzed by core laboratories blinded to
reatment assignment. A blinded events committee adjudi-
ated all events. The overall performance of the study was
able 1. Baseline Demographics
Cohort II
p
Value*
TriActiv
(n  313)
Active Control
(n  318)
emale gender, n (%) 51 (16.3) 64 (20.1) 0.21
ge (yrs), mean  SD 68.5  9.9 68.5  10.3 0.98
Range 39–99 41–93
ypertension, n (%) 269 (85.9) 264 (83.0) 0.31
iabetes mellitus, n (%) 129 (41.2) 133 (41.8) 0.88
yslipidemia†, n (%) 266 (85.0) 278 (87.4) 0.37
igarette smoking, n (%) 54 (17.3) 54 (17.0) 0.93
amily history of CAD, n (%) 92 (29.4) 107 (33.7) 0.25
rior MI, n (%) 201 (64.2) 200 (62.9) 0.73
eripheral vascular disease, n (%) 81 (25.9) 82 (25.8) 0.98
troke or TIA, n (%) 44 (14.1) 37 (11.6) 0.36
anadian cardiovascular class
I 38 (12.2) 45 (14.3) 0.39
II 75 (24.1) 84 (26.8)
III 98 (31.5) 87 (27.7)
IV 100 (32.2) 99 (31.5)
VEF (%), mean  SD 48.7  11.5 48.7  11.9 0.97
Range 25–75 25–88
TriActiv Cohort II versus Active Control. †Requiring treatment.
CAD  coronary artery disease; LVEF  left ventricular ejection fraction; MI 
yocardial infarction; TIA  transient ischemic attack.eviewed by the Data Safety Monitoring Board.
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November 1, 2005:1677–83 Evaluation of TriActiv System in the PRIDE StudyTable 2. Procedural Data
Cohort II
p Value*
TriActiv
(n  313)
Active Control
(n  318)
Number of lesions treated, mean 1.3 1.2 0.63
Range 1–4 1–4
Number of SVGs treated, n (%)
1 297 (94.9) 299 (94.0) 0.86
2 16 (5.1) 19 (6.0)
Age of SVG (yrs), mean  SD 11.9  5.8 12.0  6.0 0.87
Range 0.6–29.1 0.5–33.0
Highest ACT (s), mean  SD 305  112 326  438 0.44
Range 0–1,500 0–7,350
Occlusion time† (min), mean  SD 4.5  2.1 5.0  2.6 0.026
Range 1.0–16.6 1.5–22.1
Procedure time (min), median 58  108.2 52  50.1 0.01
Pre-procedure clopidogrel or ticlopidine, n (%) 276 (88.2) 271 (85.2) 0.28
GP IIb/IIIa planned, n (%) 167 (53.4) 167 (52.5) 0.83
GP IIb/IIIa used, n (%) 169 (54.0) 174 (54.7) 0.86
Sheath size, n (%)
5–F 1 (0.3) 0 (0) 0.001‡
6–F 5 (1.6) 35 (11.3)
7–F 149 (47.9) 149 (47.9)
8–F 157 (50.3) 127 (40.8)
*TriActiv Cohort II versus Active Control. †Occlusion time per each intervention. Occlusion time for Active Control is for
GuardWire only. ‡Comparison of 7-F used in Cohort II.
ACT  activated clotting time; GP  glycoprotein; SVG  saphenous vein graft.Table 3. Baseline Lesion Angiography
Cohort II
p Value*
TriActiv
(n  323)
Active Control
(n  322)
Lesion location, n (%)
Ostial 48 (15.0) 69 (21.6) 0.01
Proximal 123 (38.3) 86 (26.9)
Mid 118 (36.8) 134 (41.9)
Distal 32 (10.0) 31 (9.7)
Lesion length, (mm) mean  SD 14.2  10.5 13.0  8.8 0.11
Range 3.1–80.2 1.6–57.7
Tortuosity, n (%) 19 (5.9) 9 (2.8) 0.05
SVG degeneration, n (%)
0%–25% 153 (47.5) 174 (54.0)
25%–50% 105 (32.6) 90 (28.0)
50%–75% 43 (13.4) 39 (12.1) 0.21
75% 21 (6.5) 19 (5.9)
SVG degeneration score (%), mean  SD 35.9  23.1 33.0  22.4 0.12
Range 0–100 0–100
Plaque volume (mm3), mean  SD 337  298 316  267 0.35
Range 34–2,015 23–1,490
Thrombus present, n (%) 187 (58.3) 186 (57.6) 0.78
Reference vessel diameter (mm), mean  SD 3.2  0.6 3.3  0.6 0.42
Range 1.8–5.5 1.9–5.1
MLD (mm), mean  SD 1.1  0.5 1.2  0.6 0.24
Range 0–4.1 0–2.8
Diameter stenosis (%), mean  SD 65.7  14.8 64.8  15.0 0.45
Range 16.3–100 22.0–100
TIMI flow grade, n (%)
0 5 (1.6) 4 (1.3)
1 6 (1.9) 5 (1.6)
2 25 (7.8) 26 (8.1) 0.77
3 286 (88.8) 285 (89.1)*TriActiv Cohort II versus Active Control.
MLD  minimum lumen diameter; SVG  saphenous vein graft; TIMI  Thrombolysis In Myocardial Infarction.
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Evaluation of TriActiv System in the PRIDE Study November 1, 2005:1677–83tatistical methods. All analyses comparing patients in
riActiv Cohort II with those in the control group were
ade on the basis of intention-to-treat. With an assumed
ACE rate of 10%, a sample size of 618 patients would
rovide 80% power to reject the null hypothesis of inferi-
rity with a  of 6% at the 5% level of significance.
ontinuous variables were compared with t tests and
ichotomous variables by Pearson’s chi-square or Fisher
xact test if the expected number in any cell was 5.
rdinal variables (e.g., baseline CCS class, sheath size,
IMI flow grade) were tested by the Cochran-Mantel-
aenszel procedure, applying uniform scores to the ordered
ategories. All analyses were performed using SAS Version
.2 (SAS Institute, Cary, North Carolina).
ESULTS
aseline and procedural characteristics. From December
001 through March 2004, 68 sites in the U.S. and 10 sites
n Europe enrolled 894 patients in the PRIDE study, with
01 non-randomized “roll-in” patients and 62 patients
andomized in Cohort I. Given the small number of
atients in Cohort I, meaningful conclusions regarding the
uperiority of TriActiv to SVG intervention without em-
olic protection could not be made. This analysis describes
Table 4. Post-Treatment Angiography
MLD (mm), mean  SD
Range
Diameter stenosis (%), mean  SD
Range
Maximum stent diameter (mm), mean  SD
Range
Direct stenting (%)
Stent length (mm), mean  SD
Range
Maximum inflation pressure (atm), mean  SD
Range
Residual thrombus present, n (%)
Distal embolization, n (%)
Perforation, n (%)
TIMI flow grade, n (%)
0
1
2
3
TIMI frame count, mean  SD
Range
Dissection at site of protection balloon†, n (%)
None
A
B
C
D
E
F*TriActiv Cohort II versus Active Control. †Assessed only for Tri
MLD  minimum lumen diameter; TIMI  Thrombolysis Inhe outcomes of patients in Cohort II. Demographic and
rocedural data were well-matched between TriActiv and
he active control patients in Cohort II (Tables 1 and 2). No
ifferences in baseline characteristics were observed within
he control group of the GuardWire or FilterWire EX.
ngiography. Lesions randomized to the TriActiv System
roup had greater tortuosity and were less likely to be ostial
Tables 3 and 4). Device success was 94.5% in lesions
reated with TriActiv and 94.7% in active control (p 
.92). Lesion success was 99.0% with TriActiv and 99.4% in
he control group (p  0.68). After treatment, a TIMI flow
rade of 3 was observed in 99.1% of lesions in the TriActiv
roup and in 97.8% in the active control cohort.
linical outcomes. One patient in Cohort II (in the TriAc-
iv group) was lost to follow-up. Procedural success was similar
n both groups (89.4% [TriActiv] versus 90.5% [control]; p 
.64). In Cohort I, there were five in-hospital MACE (18.2%)
n the TriActiv group and three (10.3%) in the placebo group.
y 30 days, there were six in-hospital MACE (15%) in the
riActiv group and three (10.3%) in the placebo group. Given
he small number of patients in each group, there was insig-
ificant power to make statistical comparisons. For Cohort II,
he incidence of MACE at 30 days was 11.2% for TriActiv and
0.1% for the control group (relative risk  1.1%; 95%
Cohort II
p Value*
TriActiv
n  323)
Active Control
(n  322)
2.8  0.6 2.8  0.6 0.59
1.2–4.9 0–4.4
4.5  10.0 14.3  11.5 0.85
10.2–96.7 38.7–100
3.7  0.6 3.8  0.6 0.09
2.5–6.0 2.5–5.0
/201 (83.1%) 258/318 (81.1%) 0.40
0.9  7.8 20.7  7.8 0.76
2–38 8–38
4.8  3.2 14.9  3.3 0.51
0–24 4–25
37 (11.5) 30 (9.3) 0.53
5 (1.6) 2 (0.6) 0.45
1 (0.3) 4 (1.3) 0.22
1 (0.3) 2 (0.6) 0.20
0 (0) 2 (0.6)
2 (0.6) 3 (0.9)
17 (99.1) 313 (97.8)
0.2  9.7 20.2  11.9 0.94
0–60 0–99
92 (96.7) — —
6 (2.0) — —
2 (0.7) — —
0 (0) — —
0 (0) — —
0 (0) — —
1 (0.3) — —(
1

167
2
1
3
2
2Activ cases.
Myocardial Infarction.
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November 1, 2005:1677–83 Evaluation of TriActiv System in the PRIDE Studyonfidence intervals  0.67 to 1.76; p  0.65; p  0.02 for
on-inferiority) (Tables 5 and 6). Within the active control
roup, the incidence of MACE at 30 days was 10.6% for the
uardwire and 7.2% for the FilterWire. Procedure-related
ACE were 10.1% and 10.2% for the active control group
nd TriActiv System, respectively. More than 16% of patients
reated with TriActiv, GuardWire, and FilterWire EX exhib-
Table 5. Clinical Events—In-Hospital
Cohor
TriActiv
(n  313)
A
Death, n (%) 3 (1.0)
Cardiac, n (%) 3 (1.0)
Non-cardiac, n (%) 0 (0)
Myocardial infarction, n (%) 28 (9.0)
Q-wave, n (%) 3 (1.0)
Non–Q-wave, n (%) 25 (8.0)
TVR, n (%) 4 (1.3)
PCI, n (%) 3 (1.0)
CABG, n (%) 1 (0.3)
TLR 3 (1.0)
PCI, n (%) 2 (0.6)
CABG, n (%) 1 (0.3)
MACE, n (%) 31 (9.9)
Vascular complications, n (%) 34 (10.9)
Transfusion, n (%) 24 (7.7)
Hematoma 5 cm, n (%) 9 (2.9)
Retroperitoneal bleed, n (%) 1 (0.3)
Pseudoaneurysm, n (%) 3 (1.0)
Arteriovenous fistula, n (%) 1 (0.3)
Vascular repair, n (%) 2 (0.6)
Peripheral ischemia/
nerve injury, n (%)
2 (0.6)
Stroke, n (%) 1 (0.3)
*TriActiv Cohort II versus Active Control. All p values calc
chi-square test was used.
CABG  coronary artery bypass graft; CI  confide
percutaneous coronary intervention; RR  relative risk;
revascularization.
Table 6. Clinical Events Through 30 Days
Coho
TriActiv
(n  313)
Death, n (%) 4 (1.3)
Cardiac, n (%) 4 (1.3)
Non-cardiac, n (%) 0 (0)
Myocardial infarction, n (%) 31 (9.9)
Q-wave, n (%) 4 (1.3)
Non–Q-wave, n (%) 27 (8.6)
TVR, n (%) 5 (1.6)
PCI, n (%) 3 (1.0)
CABG, n (%) 2 (0.6)
TLR 4 (1.3)
PCI, n (%) 2 (0.6)
CABG, n (%) 2 (0.6)
MACE, n (%) 35 (11.2)
Stroke, n (%) 1 (0.3)
*TriActiv Cohort II versus Active Control. All p values calc
chi-squared test was used. ‡Relative risk  1.11 (one-sided
0.02 indicates non-inferiority of the TriActiv System to Active Co
Abbreviations as in Table 5.ted some degree of myonecrosis (Fig. 2). Patients in the
riActiv group were more likely to require blood transfusion.
he overall vascular complication rate was 10.9% for TriActiv
ersus 5.4% for Active Control (Table 5). Sub-group analysis
ndicated that the higher rate of transfusion in the TriActiv
ohort was associated with an early design of the hemostatic
alve in combination with 8-F guiding catheters (Fig. 3).
p Value* RR (95% CI)
Control
318)
(0.3) 0.37 3.05 (0.32–29.1)
(0.3) 0.37 3.05 (0.32–29.1)
(0) 1.0 —
(8.5) 0.84† 1.05 (0.64–1.75)
(0.3) 0.37 3.05 (0.32–29.1)
(8.2) 0.93 0.98 (0.58–1.65)
(0.6) 0.45 2.03 (0.37–11.0)
(0.6) 0.68 1.52 (0.26–9.06)
(0) 0.50 —
(0.6) 0.68 1.52 (0.26–9.06)
(0.6) 1.0 1.02 (0.14–7.17)
(0) 0.50 —
(9.1) 0.74† 1.09 (0.67–1.76)
(5.4) 0.01† 2.03 (1.16–3.56)
(3.5) 0.02† 2.22 (1.10–4.45)
(0.6) 0.03 4.57 (1.00–20.99)
(0.3) 1.0 1.02 (0.06–16.17)
(0.6) 0.68 1.52 (0.26–9.06)
(0) 0.50 —
(0.3) 0.37 3.05 (0.32–29.1)
(0.3) 0.62 2.03 (0.19–22.3)
(0.3) 1.0 1.02 (0.06–16.2)
using Fisher exact test, except where indicated by †, where
terval; MACE  major adverse cardiac events; PCI 
 target vessel revascularization; TLR  target lesion
p Value* RR (95% CI)
e Control
 318)
2 (0.6) 0.45 2.0 (0.37–11.01)
2 (0.6) 0.45 2.0 (0.37–11.01)
0 (0) 1.0 —
8 (8.8) 0.64† 1.12 (0.69–1.83)
1 (0.3) 0.21 4.06 (0.46–36.2)
7 (8.5) 0.95† 1.02 (0.61–1.69)
4 (1.3) 0.75 1.27 (0.34–4.69)
4 (1.3) 0.68 0.76 (0.17–3.38)
0 (0) 0.25 —
4 (1.3) 1.0 1.02 (0.26–4.03)
4 (1.3) 0.69 0.51 (0.09–2.75)
0 (0) 0.50 —
2 (10.1) 0.65†‡ 1.11 (0.71–1.75)
1 (0.3) 1.0 1.02 (0.06–16.2)
using Fisher exact test except where indicated by †, where
nfidence interval [CI] on the difference  5.2%; p value oft II
ctive
(n 
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Evaluation of TriActiv System in the PRIDE Study November 1, 2005:1677–83ISCUSSION
oth the TriActiv and GuardWire require transient occlu-
ion of the SVG during PCI. As observed in this study, the
as-filled balloon of the TriActiv System allows for more
apid inflation and deflation times. Using an active flush and
xtraction mechanism, the TriActiv System offers the po-
ential for greater efficiency of particle removal. The Filter-
ire captures liberated particles in a retrieval basket. Unlike
alloon occlusion systems, filter protection devices allow
ow maintenance, avoiding potential ischemic complica-
ions; however, small particles and soluble vasoconstrictors
re not always captured.
The PRIDE trial was designed to test two hypotheses:
mbolic protection with TriActiv is superior to an unpro-
ected control group, and outcomes with TriActiv are not
nferior to those with approved distal protection systems.
nitially, investigators preferred to enroll in Cohort I. With
merging data demonstrating superiority of embolic protec-
ion with the GuardWire System and FilterWire EX, most
nvestigators chose to randomize patients in Cohort II. The
imited enrollment in Cohort I underpowered the superior-
ty comparison, precluding any ability to exclude the null
ypothesis.
The PRIDE study demonstrated that embolic protection
uring SVG intervention with the TriActiv System was not
nferior to protection with the active control group of either
he balloon-occlusion Guardwire System or the Filterwire
X device. The non-inferiority design of Cohort II pre-
ludes conclusions regarding the superiority of TriActiv to
igure 2. (A) Post-treatment creatine kinase (CK)-MB and (B) total
reatine phosphokinase (CPK) elevation according to embolic protection
ystem used. ULN  upper limit of normal.ither the Filterwire EX or Guardwire devices for the
F
arevention of adverse events, although the addition of flush
nd extraction to balloon occlusion did not appear to
onfirm additional clinical benefit. Vessels randomized to
ither TriActiv or the control group had post-treatment
ates of TIMI flow grade 3 in excess of 97%, confirming a
igh degree of efficacy for all three embolic protection
evices; however, patients randomized to the TriActiv
ystem were more likely to suffer a hemorrhagic complica-
ion, but were not at higher risk of suffering a non-
emorrhagic vascular complication. When stratified accord-
ng to guiding catheter size, this higher rate of transfusion
as observed only in patients randomized to TriActiv and in
hom large guiding catheters were used. This finding is best
xplained by the greater rate of aspiration with larger
uiding catheters (200 cc/min with 8-F guiding catheters
ompared with 125 cc/min with 7-F guiding catheters).
The relatively high incidence of peri-procedural myone-
rosis observed in patients treated with any of the three
rotection devices probably reflects both the complex nature
f lesions in the PRIDE trial, and the reality that all three
evices have limitations. One of the limitations of the
riActiv System was the longer mean procedure time
ompared with the active control group. It is possible that
he extended time might have contributed to adverse events.
o address this problem, the next generation TriActiv FX
ystem, will incorporate a monorail flush catheter, a more
recise balloon inflation mechanism, and a guidewire seal-
ng mechanism allowing exchange over the back end of the
uidewire. These improvements are expected to reduce total
cclusion and procedure times.
Saphenous vein graft degeneration and pretreatment
hrombus burden are independent predictors of MACE
uring SVG intervention (7). The pre-procedure SVG
egeneration score was greater in the PRIDE trial than it
as in the FIRE trial and lesions in the PRIDE trial also
ad greater pre-procedural thrombus. Despite greater graft
egeneration and thrombus burden, the PRIDE study
emonstrated non-inferiority of the TriActiv System com-
ared with approved embolic protection devices. Advancesigure 3. Vascular/hemorrhagic complications according to treatment
ssignment and catheter size.
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November 1, 2005:1677–83 Evaluation of TriActiv System in the PRIDE Studyn balloon occlusion systems and filters (e.g., the FilterWire
Z) presumably will improve outcomes with both systems.
tudy limitations. This study has several limitations. Its
ndings are not generalizable to patients who do not meet
ntry criteria. The non-inferiority analysis precludes any
onclusions of superiority of one group over another. With
pre-specified  of 6%, statistical non-inferiority was
chieved; however, this does not establish equivalence in
erms of safety or efficacy, because the upper boundary of the
5% confidence interval allows for a relatively large differ-
nce within the bounds of non-inferiority. TriActiv could be
s much as 29% better or 75% worse than the control device
n preventing 30-day MACE. Unlike the SAFER trial, the
RIDE trial allowed enrollment of patients with aorto-
stial lesions and total occlusions. Thus, the outcomes for
atients treated with the Guardwire in both trials are not
irectly comparable. No conclusions can be drawn concern-
ng the comparison of TriActiv System to PCI without
rotection, because this arm of the trial enrolled too few
atients to justify statistical comparisons. Finally, because
he choice of Guardwire or FilterWire was left to operator
iscretion, potential selection bias precludes comparison of
ither FilterWire to Guardwire, or of either alone to
riActiv.
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omery Village, Maryland.
ata Management and Analysis: PPD Medical Device,
inneapolis, Minnesota.tudy Monitor: Bailer Research, San Ramon, California.
